Seroba Life Sciences — 2022 Investments
2 investments dated 2022 · listed companies and verified rows first · show all
Sibylla Biotech develops PPI-FIT, a drug discovery technology that uses quantum physics and mathematical modeling to characterize protein folding pathways at atomic resolution.
AI & Machine LearningBiotechDeep TechTrento, IT
Emiliano Biasini(Co-founder)inPietro Faccioli(Co-founder)inGiovanni Spagnolli(Co-founder, CTO)inMaria Letizia Barreca(Co-founder)inGraziano Lolli(Co-founder)
Co-investors3B Future Health FundCDP Venture CapitalV-Bio VenturesVertis SGRVI PartnersClaris Ventures+1 more
Perfuze develops medical devices for the treatment of acute ischemic stroke, focused on addressing unmet clinical needs in mechanical thrombectomy.
Deep TechHealthtechMedical DevicesGalway City, IE
Wayne Allen(Co-Founder, CEO, Director)inLiam Mullins(CTO and Co-founder)in
Co-investorsSV Health InvestorsEnterprise IrelandEQT Life Sciences
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.